Do analysts prefer SYBX or CANF?

Can-Fite BioPharma has a consensus price target of $44.00, suggesting a potential upside of 1,226.90%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Can-Fite BioPharma is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is SYBX or CANF more profitable?

Can-Fite BioPharma's return on equity of 0.00% beat Synlogic's return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% Can-Fite BioPharma N/A N/A N/A

Does the media refer more to SYBX or CANF?

In the previous week, Synlogic and Synlogic both had 1 articles in the media. Synlogic's average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CANF or IMNN more profitable?

Can-Fite BioPharma's return on equity of 0.00% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Can-Fite BioPharma N/A N/A N/A Imunon N/A -341.23% -153.79%

Does the media refer more to CANF or IMNN?

In the previous week, Imunon had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 2 mentions for Imunon and 1 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 0.00 equaled Imunon'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Imunon 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CANF or RNAZ more profitable?

Can-Fite BioPharma's return on equity of 0.00% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Can-Fite BioPharma N/A N/A N/A TransCode Therapeutics N/A -875.35% -50.36%

Does the media prefer CANF or RNAZ?

In the previous week, Can-Fite BioPharma and Can-Fite BioPharma both had 1 articles in the media. Can-Fite BioPharma's average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TransCode Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CANF or OBSV?

Can-Fite BioPharma presently has a consensus target price of $44.00, indicating a potential upside of 1,226.90%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, research analysts clearly believe Can-Fite BioPharma is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CANF or OBSV more profitable?

Can-Fite BioPharma's return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Can-Fite BioPharma N/A N/A N/A ObsEva N/A -416.36% -92.01%

Does the media prefer CANF or OBSV?

In the previous week, Can-Fite BioPharma and Can-Fite BioPharma both had 1 articles in the media. Can-Fite BioPharma's average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ObsEva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CANF or NXTC more profitable?

Can-Fite BioPharma's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Can-Fite BioPharma N/A N/A N/A NextCure N/A -186.96% -124.62%

Does the media refer more to CANF or NXTC?

In the previous week, NextCure had 12 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 13 mentions for NextCure and 1 mentions for Can-Fite BioPharma. NextCure's average media sentiment score of 0.67 beat Can-Fite BioPharma's score of 0.00 indicating that NextCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NextCure 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Can-Fite BioPharma (CANF) Competitors

$3.32 +0.01 (+0.18%)

As of 02:16 PM Eastern

Compare

CANF vs. SYBX, IMNN, RNAZ, OBSV, and NXTC

Should you buy Can-Fite BioPharma stock or one of its competitors? MarketBeat compares Can-Fite BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Can-Fite BioPharma include Synlogic (SYBX), Imunon (IMNN), TransCode Therapeutics (RNAZ), ObsEva (OBSV), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry.

How does Can-Fite BioPharma compare to Synlogic?

Synlogic (NASDAQ:SYBX) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Can-Fite BioPharma has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,030.80	-$23.36M	-$0.06	N/A
Can-Fite BioPharma	$405K	5.36	-$7.63M	-$22.80	N/A

63.4% of Synlogic shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 2.6% of Synlogic shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Can-Fite BioPharma has a consensus price target of $44.00, suggesting a potential upside of 1,226.90%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Can-Fite BioPharma is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Synlogic and Synlogic both had 1 articles in the media. Synlogic's average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Can-Fite BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Can-Fite BioPharma's return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Can-Fite BioPharma	N/A	N/A	N/A

Synlogic has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

Summary

Can-Fite BioPharma beats Synlogic on 9 of the 13 factors compared between the two stocks.

How does Can-Fite BioPharma compare to Imunon?

Can-Fite BioPharma (NYSE:CANF) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Can-Fite BioPharma's return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Imunon	N/A	-341.23%	-153.79%

Can-Fite BioPharma has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Imunon has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

Can-Fite BioPharma currently has a consensus target price of $44.00, suggesting a potential upside of 1,226.90%. Imunon has a consensus target price of $10.00, suggesting a potential upside of 504.23%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Can-Fite BioPharma is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Can-Fite BioPharma has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.36	-$7.63M	-$22.80	N/A
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A

In the previous week, Imunon had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 2 mentions for Imunon and 1 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 0.00 equaled Imunon'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Can-Fite BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Imunon	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by company insiders. Comparatively, 2.8% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Can-Fite BioPharma beats Imunon on 8 of the 13 factors compared between the two stocks.

How does Can-Fite BioPharma compare to TransCode Therapeutics?

Can-Fite BioPharma (NYSE:CANF) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Can-Fite BioPharma's return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
TransCode Therapeutics	N/A	-875.35%	-50.36%

21.0% of Can-Fite BioPharma shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Can-Fite BioPharma has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Can-Fite BioPharma presently has a consensus target price of $44.00, indicating a potential upside of 1,226.90%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Can-Fite BioPharma is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Can-Fite BioPharma has higher revenue and earnings than TransCode Therapeutics. TransCode Therapeutics is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.36	-$7.63M	-$22.80	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A

In the previous week, Can-Fite BioPharma and Can-Fite BioPharma both had 1 articles in the media. Can-Fite BioPharma's average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Can-Fite BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TransCode Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Can-Fite BioPharma beats TransCode Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Can-Fite BioPharma compare to ObsEva?

Can-Fite BioPharma (NYSE:CANF) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Can-Fite BioPharma has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Can-Fite BioPharma presently has a consensus target price of $44.00, indicating a potential upside of 1,226.90%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, research analysts clearly believe Can-Fite BioPharma is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Can-Fite BioPharma has higher revenue and earnings than ObsEva. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.36	-$7.63M	-$22.80	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

In the previous week, Can-Fite BioPharma and Can-Fite BioPharma both had 1 articles in the media. Can-Fite BioPharma's average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Can-Fite BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ObsEva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Can-Fite BioPharma's return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
ObsEva	N/A	-416.36%	-92.01%

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Can-Fite BioPharma beats ObsEva on 9 of the 12 factors compared between the two stocks.

How does Can-Fite BioPharma compare to NextCure?

Can-Fite BioPharma (NYSE:CANF) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Can-Fite BioPharma has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, NextCure has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

Can-Fite BioPharma's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
NextCure	N/A	-186.96%	-124.62%

Can-Fite BioPharma has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.36	-$7.63M	-$22.80	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

In the previous week, NextCure had 12 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 13 mentions for NextCure and 1 mentions for Can-Fite BioPharma. NextCure's average media sentiment score of 0.67 beat Can-Fite BioPharma's score of 0.00 indicating that NextCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Can-Fite BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Can-Fite BioPharma presently has a consensus price target of $44.00, suggesting a potential upside of 1,226.90%. NextCure has a consensus price target of $19.00, suggesting a potential upside of 268.93%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Can-Fite BioPharma is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

NextCure beats Can-Fite BioPharma on 7 of the 13 factors compared between the two stocks.

Get Can-Fite BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CANF vs. The Competition

Export

Metric	Can-Fite BioPharma	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$2.19M	$966.67M	$6.80B	$23.45B
Dividend Yield	N/A	4.84%	2.67%	4.15%
P/E Ratio	-1.87	1.51	27.00	30.94
Price / Sales	5.36	116.39	518.66	20.37
Price / Cash	N/A	22.05	26.68	18.81
Price / Book	1.88	8.87	10.68	4.76
Net Income	-$7.63M	-$2.87M	$3.59B	$1.07B
7 Day Performance	2.98%	16.29%	-0.19%	0.86%
1 Month Performance	11.28%	15.14%	1.93%	1.72%
1 Year Performance	-83.98%	38.08%	25.24%	17.87%

Can-Fite BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CANF Can-Fite BioPharma	1.69 of 5 stars	$3.32 +0.2%	$44.00 +1,226.9%	-84.0%	$2.19M	$405K	N/A	8	Gap Down
SYBX Synlogic	0.0992 of 5 stars	$0.71 -0.4%	N/A	-59.5%	$8.32M	$8K	N/A	80
IMNN Imunon	2.7986 of 5 stars	$1.97 +0.5%	$10.00 +407.6%	-78.6%	$8.24M	N/A	N/A	30	News Coverage
RNAZ TransCode Therapeutics	0.4151 of 5 stars	$8.58 +0.2%	N/A	-12.2%	$8.13M	N/A	N/A	9	News Coverage Positive News Gap Up
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CANF) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Can-Fite BioPharma (CANF) Competitors

CANF vs. SYBX, IMNN, RNAZ, OBSV, and NXTC

How does Can-Fite BioPharma compare to Synlogic?

Summary

How does Can-Fite BioPharma compare to Imunon?

Summary

How does Can-Fite BioPharma compare to TransCode Therapeutics?

Summary

How does Can-Fite BioPharma compare to ObsEva?

Summary

How does Can-Fite BioPharma compare to NextCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CANF vs. The Competition

Can-Fite BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Can-Fite BioPharma (CANF) Competitors

CANF vs. SYBX, IMNN, RNAZ, OBSV, and NXTC

How does Can-Fite BioPharma compare to Synlogic?

Which has stronger earnings & valuation, SYBX or CANF?

Do insiders & institutionals have more ownership in SYBX or CANF?

Do analysts prefer SYBX or CANF?

Does the media refer more to SYBX or CANF?

Is SYBX or CANF more profitable?

Which has more volatility & risk, SYBX or CANF?

Summary

How does Can-Fite BioPharma compare to Imunon?

Is CANF or IMNN more profitable?

Which has more risk and volatility, CANF or IMNN?

Do analysts recommend CANF or IMNN?

Which has better earnings and valuation, CANF or IMNN?

Does the media refer more to CANF or IMNN?

Do institutionals & insiders hold more shares of CANF or IMNN?

Summary

How does Can-Fite BioPharma compare to TransCode Therapeutics?

Is CANF or RNAZ more profitable?

Do institutionals and insiders have more ownership in CANF or RNAZ?

Which has more risk and volatility, CANF or RNAZ?

Do analysts rate CANF or RNAZ?

Which has preferable earnings & valuation, CANF or RNAZ?

Does the media prefer CANF or RNAZ?

Summary

How does Can-Fite BioPharma compare to ObsEva?

Which has more volatility and risk, CANF or OBSV?

Do analysts prefer CANF or OBSV?

Which has better earnings & valuation, CANF or OBSV?

Does the media prefer CANF or OBSV?

Is CANF or OBSV more profitable?

Do insiders & institutionals believe in CANF or OBSV?

Summary

How does Can-Fite BioPharma compare to NextCure?

Which has more risk and volatility, CANF or NXTC?

Is CANF or NXTC more profitable?

Which has higher earnings and valuation, CANF or NXTC?

Does the media refer more to CANF or NXTC?

Do analysts recommend CANF or NXTC?

Do institutionals & insiders have more ownership in CANF or NXTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CANF vs. The Competition

Can-Fite BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools